FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3150604098> ?p ?o ?g. }

• W3150604098 endingPage "526" @default.
• W3150604098 startingPage "520" @default.
• W3150604098 abstract "AIM: To study the safety and efficacy of pegylated interferon alfa-2b, indigenously developed in India, plus ribavirin in treatment of hepatitis C virus(HCV). METHODS: One-hundred HCV patients were enrolled in an open-label, multicenter trial. Patients were treated with pegylated interferon alfa-2b 1.5 μg/kg per week subcutaneously plus oral ribavirin 800 mg/d for patients with genotypes 2 and 3 for 24 wk. The same dose of peginterferon plus weight-based ribavirin(800 mg/d for ≤ 65 kg; 1000 mg/d for > 65-85 kg; 1200 mg/d for > 85-105 kg; 1400 mg/d for > 105 kg body weight) was administered for 48 wk for patients with genotypes 1 and 4. Serological and biochemical responses of patients were assessed.RESULTS: Eighty-two patients(35 in genotypes 1 and 4 and 47 in 2 and 3), completed the study. In genotype 1, 25.9% of patients achieved rapid virologic response(RVR): while the figures were 74.1% for early virologic response(EVR) and 44.4% for sustained virologic response(SVR). For genotypes 2 and 3, all patients bar one belonged to genotype 3, and of those, 71.4%, 87.5%, and 64.3% achieved RVR, EVR, and SVR, respectively. In genotype 4, 58.8%, 88.2%, and 52.9% of patients achieved RVR, EVR, and SVR, respectively. The majority of patients attained normal levels of alanine aminotransferase by 4-12 wk of therapy. Most patients showed a good tolerance for the treatment, although mild-to-moderate adverse events were exhibited; only two patients discontinued the study medication due to serious adverse events(SAEs). Eleven SAEs were observed in nine patients; however, only four SAEs were related to study medication.CONCLUSION: Peginterferon alfa-2b, which was developed in India, in combination with ribavirin, is a safe and effective drug in the treatment of HCV." @default.
• W3150604098 created "2021-04-13" @default.
• W3150604098 creator A5002628232 @default.
• W3150604098 creator A5002759219 @default.
• W3150604098 creator A5016197833 @default.
• W3150604098 creator A5022426968 @default.
• W3150604098 creator A5026920385 @default.
• W3150604098 creator A5032550854 @default.
• W3150604098 creator A5039622472 @default.
• W3150604098 creator A5040803666 @default.
• W3150604098 creator A5048129114 @default.
• W3150604098 creator A5050574095 @default.
• W3150604098 creator A5050680258 @default.
• W3150604098 creator A5054115285 @default.
• W3150604098 creator A5055984886 @default.
• W3150604098 creator A5055989933 @default.
• W3150604098 creator A5058431125 @default.
• W3150604098 creator A5059050988 @default.
• W3150604098 creator A5071636750 @default.
• W3150604098 creator A5072062866 @default.
• W3150604098 creator A5073856777 @default.
• W3150604098 creator A5076792928 @default.
• W3150604098 creator A5078649475 @default.
• W3150604098 creator A5085637065 @default.
• W3150604098 date "2014-01-01" @default.
• W3150604098 modified "2023-09-23" @default.
• W3150604098 title "Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C" @default.
• W3150604098 hasPublicationYear "2014" @default.
• W3150604098 type Work @default.
• W3150604098 sameAs 3150604098 @default.
• W3150604098 citedByCount "0" @default.
• W3150604098 crossrefType "journal-article" @default.
• W3150604098 hasAuthorship W3150604098A5002628232 @default.
• W3150604098 hasAuthorship W3150604098A5002759219 @default.
• W3150604098 hasAuthorship W3150604098A5016197833 @default.
• W3150604098 hasAuthorship W3150604098A5022426968 @default.
• W3150604098 hasAuthorship W3150604098A5026920385 @default.
• W3150604098 hasAuthorship W3150604098A5032550854 @default.
• W3150604098 hasAuthorship W3150604098A5039622472 @default.
• W3150604098 hasAuthorship W3150604098A5040803666 @default.
• W3150604098 hasAuthorship W3150604098A5048129114 @default.
• W3150604098 hasAuthorship W3150604098A5050574095 @default.
• W3150604098 hasAuthorship W3150604098A5050680258 @default.
• W3150604098 hasAuthorship W3150604098A5054115285 @default.
• W3150604098 hasAuthorship W3150604098A5055984886 @default.
• W3150604098 hasAuthorship W3150604098A5055989933 @default.
• W3150604098 hasAuthorship W3150604098A5058431125 @default.
• W3150604098 hasAuthorship W3150604098A5059050988 @default.
• W3150604098 hasAuthorship W3150604098A5071636750 @default.
• W3150604098 hasAuthorship W3150604098A5072062866 @default.
• W3150604098 hasAuthorship W3150604098A5073856777 @default.
• W3150604098 hasAuthorship W3150604098A5076792928 @default.
• W3150604098 hasAuthorship W3150604098A5078649475 @default.
• W3150604098 hasAuthorship W3150604098A5085637065 @default.
• W3150604098 hasConcept C126322002 @default.
• W3150604098 hasConcept C197934379 @default.
• W3150604098 hasConcept C203014093 @default.
• W3150604098 hasConcept C2522874641 @default.
• W3150604098 hasConcept C2776178377 @default.
• W3150604098 hasConcept C2776408679 @default.
• W3150604098 hasConcept C2776455275 @default.
• W3150604098 hasConcept C2776461080 @default.
• W3150604098 hasConcept C2780040827 @default.
• W3150604098 hasConcept C2909179924 @default.
• W3150604098 hasConcept C71924100 @default.
• W3150604098 hasConcept C90924648 @default.
• W3150604098 hasConceptScore W3150604098C126322002 @default.
• W3150604098 hasConceptScore W3150604098C197934379 @default.
• W3150604098 hasConceptScore W3150604098C203014093 @default.
• W3150604098 hasConceptScore W3150604098C2522874641 @default.
• W3150604098 hasConceptScore W3150604098C2776178377 @default.
• W3150604098 hasConceptScore W3150604098C2776408679 @default.
• W3150604098 hasConceptScore W3150604098C2776455275 @default.
• W3150604098 hasConceptScore W3150604098C2776461080 @default.
• W3150604098 hasConceptScore W3150604098C2780040827 @default.
• W3150604098 hasConceptScore W3150604098C2909179924 @default.
• W3150604098 hasConceptScore W3150604098C71924100 @default.
• W3150604098 hasConceptScore W3150604098C90924648 @default.
• W3150604098 hasIssue "7" @default.
• W3150604098 hasLocation W31506040981 @default.
• W3150604098 hasOpenAccess W3150604098 @default.
• W3150604098 hasPrimaryLocation W31506040981 @default.
• W3150604098 hasRelatedWork W157323825 @default.
• W3150604098 hasRelatedWork W2000558757 @default.
• W3150604098 hasRelatedWork W2014171438 @default.
• W3150604098 hasRelatedWork W2015480196 @default.
• W3150604098 hasRelatedWork W2105550293 @default.
• W3150604098 hasRelatedWork W2124192600 @default.
• W3150604098 hasRelatedWork W2127685726 @default.
• W3150604098 hasRelatedWork W2134790296 @default.
• W3150604098 hasRelatedWork W2150875695 @default.
• W3150604098 hasRelatedWork W2182218967 @default.
• W3150604098 hasRelatedWork W2365615677 @default.
• W3150604098 hasRelatedWork W2373586664 @default.
• W3150604098 hasRelatedWork W2394144301 @default.
• W3150604098 hasRelatedWork W2406082172 @default.
• W3150604098 hasRelatedWork W2416455176 @default.
• W3150604098 hasRelatedWork W255235625 @default.

• next